Thank you, Mr. Morrice. I want to thank you for your advocacy on this, and to say that Noor's case is deeply tragic and is something that lights a fire in us to do everything that we can for action.
I have two quick points. Health Canada, once it approves that a drug is going to be eligible for public reimbursement, it's then up to the provinces to make the decision about whether or not it is publicly reimbursed—I'm sorry: Health Canada approves it, and then the provinces decide if it's eligible for reimbursement.
The arm's-length decision of Canada's Drug Agency is important. Obviously, we want those science-based decisions to not be influenced by politics, but the agreements that we're signing for drugs for rare diseases are so critical. I was so excited to sign the third one in Alberta, because it's a collective commitment to expand our action on drugs for rare diseases and to show a coordinated approach to these diseases. To take cancer as an example, there are costs. We have to do a much better job.
It's pretty incredible, in this country, when you walk into the cancer ward of a hospital. I talked to a doctor there. When she started 30 years ago, the survival rate was only 30%: Today it's 90%. When I talked to those patients.... In fact, I talked to one patient about the experience of an American family member, who was wiped out entirely. They lost everything because of a cancer diagnosis. That's not our case here.
It's still too expensive. We have to do better. However, I think that seeing people where they are and recognizing the urgency of the devastating thing this does to families.... Look, it's bad enough to get a diagnosis, but then to wonder how the heck you're going to pay for your medication is just fundamentally unfair, so we have to go as fast and as far as we can.
Thank you for the question.